RxFinder RxPBM PharmaBenefits RxSaver RxNews MedicalClaim RxInsider ClinicalRx

A BuiltForAI Property

Drug class profile · refreshed daily from federal data

CTLA-4-directed Blocking Antibody

2 molecules in this class, $18.5M combined CY2024 Part D spend across 941 claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 30 May 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the CTLA-4-directed Blocking Antibody class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $18.5Mcombined across class
Total Rx claims: 941327 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

01

Ipilimumab

Brand: YERVOY · 941 Part D claims (CY24) · 327 beneficiaries · First FDA approval: 2011-03-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $18.5M

Class share

100%

of class CY24 spend

View profile →

02

Tremelimumab

Brand: IMJUDO · — Part D claims (CY24) · First FDA approval: 2022-10-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

0%

of class CY24 spend

View profile →

Related questions.

Q&A librarySourced · reviewed quarterly

pricingWhat is NADAC?pricingIs NADAC the same as my PBM cost?pricingWhat is spread pricing?pricingWhat is a NADAC pass-through PBM contract?pricingWhat's the difference between AWP, MAC, and NADAC?pricingWhat is a dispensing fee in a PBM contract?

Browse all canonical questions →